Ziconotide
Ziconotide (Prialt), synthetic omega-conotoxin MVIIA
Written by Aaron CuhaReviewed Sep 2026
Also known as: Prialt, SNX-111, omega-conotoxin MVIIA
A cone snail peptide approved in 2004 for severe chronic pain, given only by infusion into the spinal fluid through an implanted pump, with a boxed warning for severe psychiatric symptoms and neurological impairment. In its cancer and AIDS pain trial, 111 patients, mean pain score fell 53.1 percent against 18.1 percent on placebo. There is no oral, injected or topical version and there cannot be one.
Overview
Ziconotide is the synthetic form of a 25-amino-acid peptide from the venom of the marine cone snail Conus magus. The FDA approved it in December 2004 under NDA 021060 for the management of severe chronic pain in adults for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies, or intrathecal morphine. Every clause in that sentence is a restriction.
The route is the first thing to understand. Ziconotide works only when delivered directly into the cerebrospinal fluid, which in practice means a programmable pump implanted under the skin with a catheter threaded into the spinal canal. The molecule does not cross the blood brain barrier, so there is no systemic form. A tablet, a subcutaneous injection or a transdermal patch of ziconotide would do nothing, and no such product exists.
Two randomised placebo-controlled trials supported the approval, one in cancer and AIDS pain and one in chronic non-malignant pain. Both met their primary endpoint on a visual analogue pain scale. In the second trial the investigators reduced the starting dose from 0.4 to 0.1 micrograms per hour and the maximum from 7.0 to 2.4 micrograms per hour partway through the study because of adverse events, and the authors attribute the trial's adverse event burden to the original higher dosing.
The safety profile is the defining constraint rather than a footnote. Dizziness, nausea, confusional state and nystagmus each occurred in at least a quarter of patients in the pooled safety database of 1254 adults. The label carries a boxed warning for severe psychiatric symptoms and neurological impairment, and it directs clinicians not to use the drug in patients with a pre-existing history of psychosis.
Ziconotide appears in consumer peptide writing as an example of what peptides can do. It is worth being blunt about why that comparison fails: this is a last-line hospital therapy requiring a surgically implanted device, a boxed warning and specialist monitoring, and it has no relationship of any kind to a vial bought online.
Mechanism of action
A selective antagonist of N-type voltage-gated calcium channels, which sit on the presynaptic terminals of primary nociceptive afferents in the dorsal horn of the spinal cord. Blocking calcium entry at those terminals prevents release of the neurotransmitters that carry the pain signal to second-order neurons. This is an entirely non-opioid mechanism: ziconotide does not act at opioid receptors, does not produce tolerance in the way opioids do, and is not associated with respiratory depression or addiction. The same mechanism explains the neuropsychiatric adverse effects, because N-type calcium channels are not confined to pain pathways and the drug is delivered into the fluid that bathes the whole central nervous system.
Human evidence
Two randomised placebo-controlled trials underpin the approval, both positive on a pain rating scale, both in patients who had already failed other treatment including intrathecal morphine. A later meta-analysis of three monotherapy trials found a pooled responder odds ratio of 2.77 and flagged the adverse event burden.
- Cancer and AIDS pain, 111 patients: pain score improved 53.1 percent versus 18.1 percent on placebo, P below 0.001.
- Chronic non-malignant pain, 255 patients over six days: 31.2 percent versus 6.0 percent reduction in pain score.
- Both trials required a dose reduction or protocol amendment because of adverse events, which is unusual and is reported in the primary publications.
- Pooled safety database of 1254 adults, 662 patient-years of exposure, mean treatment duration 193 days, average final dose 17.6 micrograms per day.
- Adverse reactions occurring in at least a quarter of patients: dizziness, nausea, confusional state, nystagmus.
What this does not tell you: Every trial was in patients with an implanted intrathecal delivery system who had already failed conventional analgesia, so the results do not describe what ziconotide would do in anyone else, and no other route exists to test. The primary endpoint in both trials was a subjective pain rating scale over days to weeks, not function, not opioid sparing measured over the long term, and not quality of life. The meta-analysis authors state directly that methodological problems limit confidence in the pooled estimate.
Reading the research record
The reason ziconotide belongs in this archive at all is that it gets cited as proof of concept for peptide therapeutics in marketing material, and the citation is almost always stripped of the facts that make it a hospital drug.
Those facts are: an implanted pump, a boxed warning for psychiatric and neurological impairment, an adverse event profile severe enough that both pivotal trials amended their dosing mid-study, and a molecule that is inert unless placed directly into cerebrospinal fluid.
The scientific story is genuinely remarkable, a venom peptide from a predatory sea snail turned into a licensed analgesic with a completely non-opioid mechanism. That story is not evidence for anything sold to consumers.
The evidence, charted
Fig. 1 · evidence composition
2of 3 citations (67%) are in people
Counted from the citation list on this page. The Human count is the same number shown in the badge at the top. Both understate any literature larger than the sources we cite.
Fig. 2 · evidence over time
Evidence spans 3 distinct years, 2004 to 2017, counted from the citation list on this page. The newest citation on file is from 2017, more than five years ago; the published record may have gone quiet.
Fig. 3 · legal status at a glance
US
Approved
UK
Approved
AU
Approved
CA
Approved
Approved in all four jurisdictions shown. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Key studies & citations
- Human2004
Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial
Double-blind, placebo-controlled, 32 centres in the United States, Australia and the Netherlands, 111 patients aged 24 to 85 randomised 2 to 1. Mean percentage improvement in the visual analogue scale of pain intensity was 53.1 percent (95 percent CI 44.0 to 62.2) with ziconotide versus 18.1 percent (95 percent CI 4.8 to 31.4) with placebo, P below 0.001. Moderate to complete pain relief in 52.9 percent versus 17.5 percent. Primary endpoint met.
JAMA - Human2006
Intrathecal ziconotide in the treatment of chronic nonmalignant pain: a randomized, double-blind, placebo-controlled clinical trial
255 inpatients, 169 on ziconotide and 86 on placebo, treated over six days. Mean percent reduction in the visual analogue scale of pain intensity was 31.2 percent versus 6.0 percent. The protocol was amended during the trial, cutting the starting dose from 0.4 to 0.1 micrograms per hour and the maximum from 7.0 to 2.4 micrograms per hour, because of adverse events. The primary endpoint was met but at the original dosing the tolerability was not acceptable.
Neuromodulation - Review2017
Ziconotide Monotherapy: A Systematic Review of Randomised Controlled Trials
Three randomised trials of ziconotide monotherapy pooled in a random effects meta-analysis, giving an odds ratio for responders versus placebo of 2.77 (95 percent CI 1.37 to 5.59). The reviewers note that frequent serious adverse events caused two of the three studies to revise their protocols, and they raise methodological concerns that they say call the validity of the pooled result into question.
Current Neuropharmacology
Frequently asked questions
Can I get ziconotide as an injection or a tablet?
No, and you never will. It does not cross the blood brain barrier, so it only works when infused directly into the cerebrospinal fluid through a catheter and an implanted pump. There is no oral, subcutaneous, intravenous or topical product, and any vial sold as ziconotide outside a hospital pharmacy is not a usable medicine.
What is ziconotide approved for?
Management of severe chronic pain in adults for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment such as systemic analgesics, adjunctive therapies or intrathecal morphine. It is a last-line option, not a first or second choice.
Is it addictive like an opioid?
It does not act at opioid receptors, so it does not produce opioid tolerance, dependence or respiratory depression. That is the main clinical argument for it. The trade-off is a different and substantial problem: dizziness, nausea, confusional state and nystagmus each occurred in at least a quarter of patients, and the label carries a boxed warning for severe psychiatric symptoms and neurological impairment.
How well does it actually work?
In the cancer and AIDS pain trial, mean pain score fell 53.1 percent against 18.1 percent on placebo, and 52.9 percent of patients reported moderate to complete relief against 17.5 percent. In non-malignant pain the separation was smaller, 31.2 percent against 6.0 percent. Both are short-term ratings on a subjective scale in patients who had already failed everything else.
Is it related to any peptide sold online?
No. It shares the word peptide and nothing else. Ziconotide is a specific 25-amino-acid sequence with three disulfide bridges, manufactured to pharmaceutical standard, delivered by an implanted device under specialist supervision.